JP2017515795A5 - - Google Patents

Download PDF

Info

Publication number
JP2017515795A5
JP2017515795A5 JP2016559818A JP2016559818A JP2017515795A5 JP 2017515795 A5 JP2017515795 A5 JP 2017515795A5 JP 2016559818 A JP2016559818 A JP 2016559818A JP 2016559818 A JP2016559818 A JP 2016559818A JP 2017515795 A5 JP2017515795 A5 JP 2017515795A5
Authority
JP
Japan
Prior art keywords
peptide
acid sequence
seq
amino acid
length
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2016559818A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017515795A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/057257 external-priority patent/WO2015150491A1/en
Publication of JP2017515795A publication Critical patent/JP2017515795A/ja
Publication of JP2017515795A5 publication Critical patent/JP2017515795A5/ja
Ceased legal-status Critical Current

Links

JP2016559818A 2014-04-01 2015-04-01 単離されたドナーｍｈｃ由来ペプチド及びその使用 Ceased JP2017515795A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14163081 2014-04-01
EP14163081.4 2014-04-01
PCT/EP2015/057257 WO2015150491A1 (en) 2014-04-01 2015-04-01 An isolated donor mhc-derived peptide and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019219661A Division JP2020055845A (ja) 2014-04-01 2019-12-04 単離されたドナーｍｈｃ由来ペプチド及びその使用

Publications (2)

Publication Number Publication Date
JP2017515795A JP2017515795A (ja) 2017-06-15
JP2017515795A5 true JP2017515795A5 (enExample) 2018-03-01

Family

ID=50390011

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016559818A Ceased JP2017515795A (ja) 2014-04-01 2015-04-01 単離されたドナーｍｈｃ由来ペプチド及びその使用
JP2019219661A Pending JP2020055845A (ja) 2014-04-01 2019-12-04 単離されたドナーｍｈｃ由来ペプチド及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019219661A Pending JP2020055845A (ja) 2014-04-01 2019-12-04 単離されたドナーｍｈｃ由来ペプチド及びその使用

Country Status (5)

Country Link
US (1) US10105425B2 (enExample)
EP (1) EP3126377B1 (enExample)
JP (2) JP2017515795A (enExample)
ES (1) ES2749073T3 (enExample)
WO (1) WO2015150491A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102411975B1 (ko) * 2016-04-06 2022-06-22 이매틱스 바이오테크놀로지스 게엠베하 Aml 및 다른 암에 대한 면역요법에 사용하기 위한 펩티드 및 펩티드의 조합
WO2019099788A1 (en) * 2017-11-16 2019-05-23 Benaroya Sesearch Institute At Virginia Mason Antigen-specific t regulatory cell assay
JP7609775B2 (ja) * 2018-12-14 2025-01-07 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） 単離されたＭＨＣ由来ヒトペプチドおよびＣＤ８＋ＣＤ４５ＲＣｌｏｗＴｒｅｇの抑制機能を刺激し、かつ活性化するためのその使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0563485A1 (en) 1992-03-30 1993-10-06 Schering-Plough In vitro generation of human dendritic cells and uses thereof
AU687733B2 (en) 1992-04-01 1998-03-05 Rockefeller University, The Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
US5635363A (en) 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
FR2798128B1 (fr) 1999-09-06 2001-11-16 Inst Nat Sante Rech Med Moyens de detection et de purification de populations lymphocytaires t cd8+ specifiques de peptides presentes dans le contexte hla
PL1642905T3 (pl) * 2004-10-02 2009-04-30 Immatics Biotechnologies Gmbh Epitopy immunogenicznych komórek pomocniczych T z antygenów guzów ludzkich oraz sposoby immunoterapeutyczne wykorzystujące te epitopy
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy

Similar Documents

Publication Publication Date Title
US20250134978A1 (en) Rna cancer vaccines
O’Keeffe et al. Human dendritic cell subsets and function in health and disease
Kim et al. Combining cancer vaccines with immunotherapy: establishing a new immunological approach
AR127118A2 (es) Péptidos y combinación de péptidos novedosos para su uso en inmunoterapia contra diversos tumores
JP2014534202A5 (enExample)
JP2020528744A5 (enExample)
JP2018523668A5 (enExample)
JP2019509029A5 (enExample)
CL2019003426A1 (es) Nuevos péptidos (seq id n°174), combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer. (divisional solicitud 201800545)
Monti et al. Human plasmacytoid dendritic cells and cutaneous melanoma
JP2017516752A5 (enExample)
JP2015510393A5 (enExample)
Broomfield et al. Transient inhibition of type I interferon enhances CD8+ T cell stemness and vaccine protection
EP2030984A4 (en) DERIVED FROM SPARC CANCER EXHAUSTANTEPEPTIDE AND PHARMACEUTICALS CONTAINING THEREOF
MX2009007261A (es) Vacuna de peptido foxp3.
FI3380115T3 (fi) Peptidejä piwil1:stä
WO2015150492A3 (en) An isolated donor mhc-derived peptide and uses thereof
JP5829517B2 (ja) 不溶性蛋白質及び／又はペプチドの可溶化方法
JP2012526519A5 (enExample)
RU2011150283A (ru) Пептиды ттк и вакцины, их содержащие
EP3868778A3 (en) Cdc45l peptides and vaccines including the same
UA124331C2 (uk) Пептид, здатний зв'язуватися з молекулою головного комплексу гістосумісності (mhc) людини i класу
Ruan et al. Transplanted human umbilical cord mesenchymal stem cells facilitate lesion repair in B6. Fas mice
Ayala et al. Commensal bacteria promote type I interferon signaling to maintain immune tolerance
Liu et al. Evaluation of the impact of arginine–chitosan/DNA nanoparticles on human naive CD4+ T cells